Surgical Therapy for Peri‐Implantitis Using Deproteinised Bovine Bone Mineral With 10% Collagen, Enamel Matrix Derivative and Doxycycline: A Prospective Cohort 10‐Year Implant Study
Journal of Clinical Periodontology · 2026
DOI: 10.1111/jcpe.70175 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Periodontology, 2026. Verfasst von Faustino Mercado und 1 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Dentistry, University of Otago, Dunedin, Otago, New Zealand. Hauptthemen laut MEDLINE: Peri-Implantitis, Doxycycline, Anti-Bacterial Agents, Dental Enamel Proteins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Health and Medical Research Council Australia.
Abstract (Originalsprache)
Aim
To assess 10‐year implant survival following surgical management of peri‐implantitis using deproteinised bovine bone mineral with 10% collagen (DBBMC), enamel matrix derivative (EMD) and doxycycline powder. Materials and Methods The original population comprised 30 non‐smoking, periodontally stable patients (mean age = 44.9 ± 11 years; 64% female; full‐mouth plaque and bleeding score < 20%, no bleeding residual periodontal pockets ≥ 4 mm), each with a single peri‐implantitis‐affected implant (bleeding on probing, probing depth > 6 mm, ≥ 20% radiographic bone loss, implants in function ≥ 2 years). The surgical procedure involved implant surface decontamination with 24% EDTA followed by defect fill with DBBMC/EMD/doxycycline mixture. Patients underwent individualised supportive peri‐implant therapy (SPIT) comprising regular clinical monitoring, professional cleaning and antimicrobial protocols for 10 years.
Results
Twenty‐nine of the 30 implants survived (96.6% survival rate). Mean probing depth decreased from 8.90 ± 1.9 mm to 3.06 ± 0.98 mm; radiographic bone loss improved from 57% ± 16.5% to 13% ± 2.5%. During 10‐year SPIT, 12 implants required adjunctive azithromycin. Fifty‐eight percent achieved the successful treatment outcome criterion (SOTC: probing depth < 5 mm, no bone loss 10% from baseline, absence of bleeding on probing/suppuration and recession < 0.5 mm anterior/1.5 mm posterior implants).
Conclusion
Surgical management of peri‐implantitis combined with DBBMC/EMD/doxycycline and personalised SPIT achieved high long‐term implant survival and stable clinical outcomes over 10 years.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Dentistry, University of Otago, Dunedin, Otago, New Zealand.
- Sir John Walsh Research Institute, University of Otago, Dunedin, Otago, New Zealand.
- School of Dentistry, University of Queensland, Brisbane, Australia.
ORCID-Profile: Faustino Mercado, Saso Ivanovski
Förderung
- National Health and Medical Research Council Australia
Zitieren
APA
Mercado, F., & Ivanovski, S. (2026). Surgical Therapy for Peri‐Implantitis Using Deproteinised Bovine Bone Mineral With 10% Collagen, Enamel Matrix Derivative and Doxycycline: A Prospective Cohort 10‐Year Implant Study. Journal of Clinical Periodontology. https://doi.org/10.1111/jcpe.70175
Vancouver
Mercado F, Ivanovski S. Surgical Therapy for Peri‐Implantitis Using Deproteinised Bovine Bone Mineral With 10% Collagen, Enamel Matrix Derivative and Doxycycline: A Prospective Cohort 10‐Year Implant Study. Journal of Clinical Periodontology. 2026. doi:10.1111/jcpe.70175
BibTeX
@article{Mercado2026,
author = {Mercado, Faustino and Ivanovski, Saso},
title = {Surgical Therapy for Peri‐Implantitis Using Deproteinised Bovine Bone Mineral With 10% Collagen, Enamel Matrix Derivative and Doxycycline: A Prospective Cohort 10‐Year Implant Study},
journal = {Journal of Clinical Periodontology},
year = {2026},
doi = {10.1111/jcpe.70175}
}
EUVIMED